CN103209994B - 可用于被动流感免疫的抗体 - Google Patents

可用于被动流感免疫的抗体 Download PDF

Info

Publication number
CN103209994B
CN103209994B CN201180035923.5A CN201180035923A CN103209994B CN 103209994 B CN103209994 B CN 103209994B CN 201180035923 A CN201180035923 A CN 201180035923A CN 103209994 B CN103209994 B CN 103209994B
Authority
CN
China
Prior art keywords
seq
sequence
variable region
fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180035923.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103209994A (zh
Inventor
劳伦斯·M·卡乌瓦尔
斯托特·埃尔斯沃思
威廉·乌辛格
克里斯塔·莫琳·麦卡琴
明哈·帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Priority to CN201610806357.8A priority Critical patent/CN106397584A/zh
Publication of CN103209994A publication Critical patent/CN103209994A/zh
Application granted granted Critical
Publication of CN103209994B publication Critical patent/CN103209994B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180035923.5A 2010-06-17 2011-06-17 可用于被动流感免疫的抗体 Expired - Fee Related CN103209994B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610806357.8A CN106397584A (zh) 2010-06-17 2011-06-17 可用于被动流感免疫的抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US61/355,978 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US61/443,103 2011-02-15
US201161445455P 2011-02-22 2011-02-22
US61/445,455 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610806357.8A Division CN106397584A (zh) 2010-06-17 2011-06-17 可用于被动流感免疫的抗体

Publications (2)

Publication Number Publication Date
CN103209994A CN103209994A (zh) 2013-07-17
CN103209994B true CN103209994B (zh) 2016-10-12

Family

ID=45348575

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180035923.5A Expired - Fee Related CN103209994B (zh) 2010-06-17 2011-06-17 可用于被动流感免疫的抗体
CN201610806357.8A Pending CN106397584A (zh) 2010-06-17 2011-06-17 可用于被动流感免疫的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610806357.8A Pending CN106397584A (zh) 2010-06-17 2011-06-17 可用于被动流感免疫的抗体

Country Status (12)

Country Link
US (1) US10676520B2 (2)
EP (1) EP2582721B1 (2)
JP (1) JP6050747B2 (2)
KR (1) KR101849738B1 (2)
CN (2) CN103209994B (2)
AU (2) AU2011268072C1 (2)
BR (1) BR112012032185A2 (2)
CA (1) CA2839421C (2)
DK (1) DK2582721T3 (2)
ES (1) ES2687706T3 (2)
RU (1) RU2635999C2 (2)
WO (1) WO2011160083A1 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2686526T3 (es) 2011-12-05 2018-10-18 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la influenza
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG10201700488QA (en) 2012-11-13 2017-02-27 Genentech Inc Anti-hemagglutinin antibodies and methods of use
US11827693B2 (en) 2013-03-14 2023-11-28 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US10639370B2 (en) * 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
EP3119802B1 (en) * 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
RU2019102746A (ru) * 2016-07-14 2020-08-14 Биоарктик Аб Белок для транспорта в мозг
EP3731862A1 (en) * 2017-12-29 2020-11-04 Development Center for Biotechnology A universal vaccine against influenza
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
WO2010010466A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
KR20050114225A (ko) 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
RU2366662C2 (ru) * 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
EP2024393A2 (en) * 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
TW201019959A (en) 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
WO2010074656A1 (en) 2008-12-24 2010-07-01 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
WO2012021786A2 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
WO2010010466A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection;Nayana Prabhu等;《JOURNAL OF VIROLOGY》;20090331;第83卷(第6期);全文 *

Also Published As

Publication number Publication date
AU2011268072A2 (en) 2013-02-28
CA2839421A1 (en) 2011-12-22
BR112012032185A2 (pt) 2016-10-11
EP2582721A1 (en) 2013-04-24
EP2582721A4 (en) 2013-11-20
JP6050747B2 (ja) 2016-12-21
WO2011160083A1 (en) 2011-12-22
US10676520B2 (en) 2020-06-09
ES2687706T3 (es) 2018-10-26
AU2011268072A1 (en) 2013-01-31
KR101849738B1 (ko) 2018-04-17
AU2011268072B2 (en) 2017-03-09
KR20130137584A (ko) 2013-12-17
AU2017203924A1 (en) 2017-07-06
CN106397584A (zh) 2017-02-15
CA2839421C (en) 2019-12-03
JP2013531993A (ja) 2013-08-15
CN103209994A (zh) 2013-07-17
US20120020971A1 (en) 2012-01-26
RU2013102073A (ru) 2014-07-27
RU2635999C2 (ru) 2017-11-17
DK2582721T3 (en) 2018-10-01
EP2582721B1 (en) 2018-08-22
AU2011268072C1 (en) 2017-10-19
AU2017203924B2 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
CN103209994B (zh) 可用于被动流感免疫的抗体
US10815294B2 (en) Neutralizing anti-influenza A virus antibodies and uses thereof
US8871207B2 (en) Neutralizing anti-influenza A virus antibodies and uses thereof
JP6371222B2 (ja) インフルエンザの受動免疫用抗体
HK1184474B (en) Antibodies useful in passive influenza immunization
HK1184474A (en) Antibodies useful in passive influenza immunization
NZ626716B2 (en) Antibodies useful in passive influenza immunization
HK1203410B (en) Antibodies useful in passive influenza immunization
EP3122772A1 (en) Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza a h5n1 clades

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161012

Termination date: 20210617

CF01 Termination of patent right due to non-payment of annual fee